タカハシ　カンジ   TAKAHASHI KANJI   髙橋　寛二    所属   関西医科大学  眼科学講座    職種   非常勤講師
論文種別	原著(症例報告除く)
言語種別	英語
査読の有無	査読あり
表題	RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.
掲載誌名	正式名：Ophthalmology 略　 称：Ophthalmology ISSNコード：01616420/15494713
巻・号・頁	121(3),pp.682–692
著者・共著者	Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, Wong TY, Silva R, Pilz S, Gekkieva M; RADIANCE Study Group.
担当区分	筆頭著者
発行年月	2014/03
概要	OBJECTIVE: To compare the efficacy and safety of ranibizumab 0.5 mg, guided by visual acuity (VA) stabilization or disease activity criteria, versus verteporfin photodynamic therapy (vPDT) in patients with visual impairment due to myopic choroidal neovascularization (CNV). DESIGN: Phase III, 12-month, randomized, double-masked, multicenter, active-controlled study. PARTICIPANTS: Patients (N = 277) with visual impairment due to myopic CNV. METHODS: Patients were randomized to receive ranibizumab on day 1, month 1, and thereafter as needed guided by VA stabilization criteria (group I, n = 106); ranibizumab on day 1 and thereafter as needed guided by disease activity criteria (group II, n = 116); or vPDT on day 1 and disease activity treated with ranibizumab or vPDT at investigators' discretion from month 3 (group III, n = 55). MAIN OUTCOME MEASURES: Mean average best-corrected visual acuity (BCVA) change from baseline to month 1 through months 3 (primary) and 6, mean BCVA change and safety over 12 months
DOI	10.1016/j.ophtha.2013.10.023
文献番号	24326106